share_log

Pfizer Inc. (NYSE:PFE) Is Foundation Resource Management Inc.'s 9th Largest Position

Pfizer Inc. (NYSE:PFE) Is Foundation Resource Management Inc.'s 9th Largest Position

辉瑞(纽约证券交易所代码:PFE)是基金会资源管理公司的第9大头寸
Defense World ·  2022/09/25 21:01

Foundation Resource Management Inc. decreased its stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 0.3% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 394,929 shares of the biopharmaceutical company's stock after selling 1,337 shares during the period. Pfizer accounts for 3.7% of Foundation Resource Management Inc.'s investment portfolio, making the stock its 9th biggest position. Foundation Resource Management Inc.'s holdings in Pfizer were worth $20,706,000 as of its most recent filing with the SEC.

据基金会资源管理公司提交给美国证券交易委员会的最新Form 13F文件显示,该公司在第二季度减持了辉瑞的股份0.3%。该机构投资者在此期间出售了1,337股后,持有这家生物制药公司的394,929股股票。辉瑞占Foundation Resources Management Inc.投资组合的3.7%,使辉瑞成为辉瑞第9大持仓。截至基金会资源管理公司最近提交给美国证券交易委员会的文件,辉瑞所持辉瑞股份价值20,70.6万美元。

Several other hedge funds also recently bought and sold shares of PFE. Piscataqua Savings Bank raised its holdings in Pfizer by 0.8% during the second quarter. Piscataqua Savings Bank now owns 25,820 shares of the biopharmaceutical company's stock valued at $1,354,000 after buying an additional 197 shares in the last quarter. Birinyi Associates Inc. raised its holdings in Pfizer by 3.4% during the first quarter. Birinyi Associates Inc. now owns 6,000 shares of the biopharmaceutical company's stock valued at $311,000 after buying an additional 200 shares in the last quarter. Curbstone Financial Management Corp raised its holdings in Pfizer by 0.3% during the first quarter. Curbstone Financial Management Corp now owns 65,901 shares of the biopharmaceutical company's stock valued at $3,412,000 after buying an additional 200 shares in the last quarter. Douglass Winthrop Advisors LLC raised its holdings in Pfizer by 0.3% during the first quarter. Douglass Winthrop Advisors LLC now owns 57,804 shares of the biopharmaceutical company's stock valued at $2,993,000 after buying an additional 200 shares in the last quarter. Finally, LifeSteps Financial Inc. raised its holdings in Pfizer by 2.5% during the second quarter. LifeSteps Financial Inc. now owns 8,179 shares of the biopharmaceutical company's stock valued at $429,000 after buying an additional 201 shares in the last quarter. Hedge funds and other institutional investors own 67.90% of the company's stock.

其他几家对冲基金最近也买卖了PFE的股票。Piscataqua Savings Bank在第二季度增持了0.8%的辉瑞股份。Piscataqua Savings Bank现在持有这家生物制药公司25,820股股票,价值1,354,000美元,上个季度又购买了197股。Birinyi Associates Inc.在第一季度将其在辉瑞的持股增加了3.4%。Birinyi Associates Inc.现在持有这家生物制药公司6,000股股票,价值311,000美元,上个季度又购买了200股。第一季度,Curbstone Financial Management Corp将其在辉瑞的持股增加了0.3%。Curbstone Financial Management Corp目前持有这家生物制药公司65,901股股票,价值3,412,000美元,此前该公司在上个季度又购买了200股。道格拉斯·温斯罗普顾问公司第一季度将其在辉瑞的持有量增加了0.3%。DouGlass Winthrop Advisors LLC现在拥有这家生物制药公司57,804股股票,价值2993,000美元,上个季度又购买了200股。最后,LifeSteps Financial Inc.在第二季度增持了2.5%的辉瑞股份。LifeSteps Financial Inc.现在持有这家生物制药公司8,179股股票,价值42.9万美元,上个季度又购买了201股。对冲基金和其他机构投资者持有该公司67.90%的股票。

Get
到达
Pfizer
辉瑞公司
alerts:
警报:

Analysts Set New Price Targets

分析师设定新的价格目标

PFE has been the topic of several recent research reports. SVB Leerink cut their target price on Pfizer from $55.00 to $53.00 and set a "market perform" rating on the stock in a report on Friday, July 29th. Morgan Stanley lowered their price target on Pfizer from $52.00 to $49.00 and set an "equal weight" rating on the stock in a research report on Friday, July 8th. UBS Group set a $59.00 price target on Pfizer in a research report on Thursday, September 1st. The Goldman Sachs Group set a $50.00 price target on Pfizer in a research report on Thursday, September 1st. Finally, Barclays set a $50.00 price target on Pfizer in a research report on Thursday, September 1st. Nine investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $57.00.

PFE一直是最近几份研究报告的主题。SVB Leerink在7月29日周五的一份报告中将辉瑞的目标价从55.00美元下调至53.00美元,并对该股设定了“市场表现”评级。摩根士丹利在7月8日周五的一份研究报告中将他们对辉瑞的目标价从52.00美元下调至49.00美元,并对该股设定了“同等权重”的评级。瑞银集团在9月1日周四的一份研究报告中为辉瑞设定了59.00美元的目标价。9月1日星期四,高盛在一份研究报告中为辉瑞设定了50美元的目标价。最后,巴克莱在9月1日周四的一份研究报告中为辉瑞设定了50.00美元的目标价。9名投资分析师对该股的评级为持有,10名分析师给出了买入评级,一名分析师给出了该公司股票的强力买入评级。根据MarketBeat.com的数据,该公司目前的共识评级为“适度买入”,共识目标价为57.00美元。

Pfizer Stock Down 1.1 %

辉瑞股价下跌1.1%

PFE stock opened at $44.08 on Friday. Pfizer Inc. has a twelve month low of $40.94 and a twelve month high of $61.71. The company has a market cap of $247.39 billion, a PE ratio of 8.63, a price-to-earnings-growth ratio of 0.54 and a beta of 0.70. The business's 50-day simple moving average is $48.24 and its 200 day simple moving average is $50.32. The company has a quick ratio of 1.20, a current ratio of 1.42 and a debt-to-equity ratio of 0.39.
上周五,PFE股价开盘报44.08美元。辉瑞公司股价跌至40.94美元的12个月低点和61.71美元的12个月高点。该公司市值为2,473.9亿美元,市盈率为8.63,市盈率为0.54,贝塔系数为0.70。该业务的50日简单移动均线切入位在48.24美元,200日简单移动均线切入位在50.32美元。该公司的速动比率为1.20,流动比率为1.42,债务权益比为0.39。

Pfizer (NYSE:PFE – Get Rating) last announced its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts' consensus estimates of $1.95 by $0.09. The firm had revenue of $27.74 billion during the quarter, compared to analysts' expectations of $26.20 billion. Pfizer had a net margin of 28.92% and a return on equity of 43.18%. The company's revenue for the quarter was up 46.8% compared to the same quarter last year. During the same quarter last year, the company earned $1.07 earnings per share. On average, research analysts anticipate that Pfizer Inc. will post 6.54 earnings per share for the current year.

辉瑞(NYSE:PFE-GET Rating)上一次公布季度收益是在7月28日星期四。这家生物制药公司公布本季度每股收益为2.04美元,比分析师普遍预期的1.95美元高出0.09美元。该公司本季度营收为277.4亿美元,高于分析师预期的262亿美元。辉瑞的净利润率为28.92%,股本回报率为43.18%。该公司本季度的收入与去年同期相比增长了46.8%。去年同期,该公司每股收益为1.07美元。研究分析师平均预计,辉瑞公司本年度每股收益将达到6.54美元。

Pfizer Announces Dividend

辉瑞宣布分红

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 5th. Shareholders of record on Friday, November 4th will be paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 3.63%. The ex-dividend date of this dividend is Thursday, November 3rd. Pfizer's dividend payout ratio is 31.31%.

该公司最近还宣布了季度股息,将于12月5日(星期一)支付。11月4日(星期五)登记在册的股东将获得每股0.40美元的股息。这意味着年化股息为1.60美元,收益率为3.63%。本次股息除息日期为11月3日(星期四)。辉瑞的派息比率为31.31%。

About Pfizer

关于辉瑞公司

(Get Rating)

(获取评级)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

辉瑞在全球发现、开发、制造、营销、分销和销售生物制药产品。该公司在不同的治疗领域提供药物和疫苗,包括Premarin系列和Eiquis品牌的心血管代谢和妇女健康;Ibrance、Xtandi、Sutent、Inlyta、Retacritt、Lorbrena和Braftovi品牌的生物制品、小分子、免疫疗法和生物仿制药;舒必乐、Medrol、Zavicefta、Zithromax、Vfend、Panzyga和Paxlovid品牌的无菌注射和抗感染药物以及口服新冠肺炎治疗。

Further Reading

进一步阅读

  • Get a free copy of the StockNews.com research report on Pfizer (PFE)
  • Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
  • MarketBeat: Week in Review 9/19 – 9/23
  • Why Does Tesla Stock Remain Resilient?
  • Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
  • Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
  • 免费获取StockNews.com关于辉瑞的研究报告
  • 华尔街对Datadog的热情会带来巨大的收益吗?
  • MarketBeat:回顾一周9/19-9/23
  • 为什么特斯拉的股票保持弹性?
  • 好市多盈利后价格疲软是买入的好时机吗?
  • 小盘股的裁员是楼市的晴雨表吗?

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

接受辉瑞日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对辉瑞及相关公司评级的每日简明摘要。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发